These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35259259)

  • 1. FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.
    Casak SJ; Pradhan S; Fashoyin-Aje LA; Ren Y; Shen YL; Xu Y; Chow ECY; Xiong Y; Zirklelbach JF; Liu J; Charlab R; Pierce WF; Fesenko N; Beaver JA; Pazdur R; Kluetz PG; Lemery SJ
    Clin Cancer Res; 2022 Jul; 28(13):2733-2737. PubMed ID: 35259259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
    Zhu AX; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DVT; Borad MJ; Bridgewater JA; Harris WP; Murphy AG; Oh DY; Whisenant JR; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Chamberlain CX; Aguado-Fraile E; Choe S; Wu B; Liu H; Gliser C; Pandya SS; Valle JW; Abou-Alfa GK
    JAMA Oncol; 2021 Nov; 7(11):1669-1677. PubMed ID: 34554208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Abou-Alfa GK; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DV; Borad MJ; Bridgewater J; Harris WP; Murphy AG; Oh DY; Whisenant J; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Fan B; Wu B; Chamberlain CX; Jiang L; Gliser C; Pandya SS; Valle JW; Zhu AX
    Lancet Oncol; 2020 Jun; 21(6):796-807. PubMed ID: 32416072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
    Lowery MA; Burris HA; Janku F; Shroff RT; Cleary JM; Azad NS; Goyal L; Maher EA; Gore L; Hollebecque A; Beeram M; Trent JC; Jiang L; Fan B; Aguado-Fraile E; Choe S; Wu B; Gliser C; Agresta SV; Pandya SS; Zhu AX; Abou-Alfa GK
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):711-720. PubMed ID: 31300360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.
    Lavacchi D; Caliman E; Rossi G; Buttitta E; Botteri C; Fancelli S; Pellegrini E; Roviello G; Pillozzi S; Antonuzzo L
    Pharmacol Ther; 2022 Sep; 237():108170. PubMed ID: 35296436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis.
    Rimini M; Burgio V; Antonuzzo L; Rimassa L; Oneda E; Lavacchi D; Personeni N; Ratti F; Pedica F; Della Corte A; Persano M; De Cobelli F; Aldrighetti L; Scartozzi M; Cascinu S; Casadei-Gardini A
    Target Oncol; 2022 Sep; 17(5):591-596. PubMed ID: 36114954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivosidenib: A Review in Advanced Cholangiocarcinoma.
    Frampton JE
    Target Oncol; 2023 Nov; 18(6):973-980. PubMed ID: 37855990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
    Corrigan L; Lowery M
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):475-481. PubMed ID: 33836133
    [No Abstract]   [Full Text] [Related]  

  • 9. Ivosidenib Boosts OS in Cholangiocarcinoma.
    Cancer Discov; 2021 Dec; 11(12):2953-2954. PubMed ID: 34635569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.
    Fan B; Abou-Alfa GK; Zhu AX; Pandya SS; Jia H; Yin F; Gliser C; Hua Z; Hossain M; Yang H
    Cancer Chemother Pharmacol; 2024 May; 93(5):471-479. PubMed ID: 38278871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
    Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan.
    Chen KA; Huang WM; Chen EY; Ho PK; Chueh CH; Wen YW; Chen MH; Chiang NJ; Tsai YW
    BMC Cancer; 2024 May; 24(1):622. PubMed ID: 38778261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
    Patel TH; Marcus L; Horiba MN; Donoghue M; Chatterjee S; Mishra-Kalyani PS; Schuck RN; Li Y; Zhang X; Fourie Zirkelbach J; Charlab R; Liu J; Yang Y; Lemery SJ; Pazdur R; Theoret MR; Fashoyin-Aje LA
    Clin Cancer Res; 2023 Mar; 29(5):838-842. PubMed ID: 36206041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.
    Woods A; Norsworthy KJ; Wang X; Vallejo J; Chiu Yuen Chow E; Li RJ; Sun J; Charlab R; Jiang X; Pazdur R; Theoret MR; de Claro RA
    Clin Cancer Res; 2024 Apr; 30(7):1226-1231. PubMed ID: 38010220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy].
    Rabehi T; Quesada S
    Bull Cancer; 2023 Dec; 110(12):1230-1231. PubMed ID: 37704495
    [No Abstract]   [Full Text] [Related]  

  • 17. Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports.
    Müller C; Franke S; Reisländer T; Keitel V; Venerito M
    Case Rep Oncol; 2024; 17(1):753-762. PubMed ID: 39015644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date.
    Uson Junior PLS; Borad MJ
    Cancer Manag Res; 2023; 15():1025-1031. PubMed ID: 37746315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience.
    Rimini M; Burgio V; Antonuzzo L; Rimassa L; Oneda E; Soldà C; Cito P; Nasti G; Lavacchi D; Zanuso V; Rizzato MD; Zaniboni A; Ottaiano A; Persano M; Cornara N; Scartozzi M; Cascinu S; Casadei-Gardini A
    Ther Adv Med Oncol; 2023; 15():17588359231171574. PubMed ID: 37457302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-
    Aguado-Fraile E; Tassinari A; Ishii Y; Sigel C; Lowery MA; Goyal L; Gliser C; Jiang L; Pandya SS; Wu B; Bardeesy N; Choe S; Deshpande V
    Future Oncol; 2021 Jun; 17(16):2057-2074. PubMed ID: 33709779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.